Fig. 5
Oxymatrine rescues megakaryopoiesis in the bone marrow (BM) and spleen after acute radiation injury. (A) Representative images of hematoxylin and eosin (H&E) staining of BM from control group, model group, thrombopoietin (TPO)-treated (3000 U/kg) group, and oxymatrine-treated (20 mg/kg) group after treatment for 12 days. (B) The histogram exhibits the counts of BM megakaryocyte (MK) in each group (n = 3 per group). (C) Representative images of H&E staining of spleens from each group after treatment for 12 days. (D) The histogram shows the counts of spleen MKs in each group (n = 3 per group). (E) The analysis of c-Kit+/CD41? (hematopoietic progenitor cells), c-Kit+/CD41+ (megakaryocytic progenitor cells), and c-Kit-/CD41+ (MKs) cell expression in each group after treatment for 12 days performed by flow cytometry. (F) The histogram exhibits the percentage of c-Kit+/CD41?, c-Kit+/CD41+, and c-Kit-/CD41+ cells in each group (n = 3 per group). (G) The expression of CD61 and CD41 in both BM MKs and spleen MKs was detected by flow cytometry after treatment for 12 days. (H) The histogram shows the percentage of CD41+/CD61+ cells in BM MKs of each groups (n = 3 per group). (I) The histogram shows the percentage of CD41+/CD61+ cells in spleen MKs of each group (n = 3 per group). Data represent the mean ± standard deviation (SD) of three independent experiments. ?P < 0.05, ??P < 0.01, and ???P < 0.001 vs. the model group. PE: phycoerythrin; FITC: fluorescein isothiocyanate; UL: upper left; UR: upper right; LL: lower left; LR: lower right |